- Stocks
- Pharma & Healthcare
- SMS Pharmaceuticals
SMS Pharmaceuticals share price
NSE: SMSPHARMAPharma & HealthcareDrug Manufacturers - General
SMS Pharmaceuticals at a glance
SMS Pharmaceuticals (NSE: SMSPHARMA) closed at ₹434.55 on 22 Oct 2026, up 0.59% on the day. With a market capitalisation of ₹4,070 Cr, it ranks 863rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 39× trailing earnings, against a return on equity of 10.8% in FY25. Over the past year the share price has risen 59.0%. Its 52-week range is ₹270.10 (24 Nov 2025) to ₹494.45 (22 Sep 2026); the last close is 12.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹207 Cr (+5.6% year on year) and net profit ₹20 Cr (+8.0%), on a consolidated basis. Promoters held 68.07% of the company as of 30 Jun 2026; 17.99% of promoter shares were pledged.
Key numbers
- Market cap
- ₹4,070 CrRank 863 on NSE
- P/E (trailing)
- 39×
- Price to book
- 2.95×FY25
- EPS (TTM)
- ₹11.24to Q1 FY27
- ROE
- 10.8%FY25
- ROCE
- 13.4%FY25
- Debt to equity
- 0.49FY25
- Net profit margin
- 8.6%FY25
- Book value / share
- ₹72.15FY25
- Dividend payout
- 4.9%FY25
- 52-week high
- ₹494.4522 Sep 2026
- 52-week low
- ₹270.1024 Nov 2025
- 1-year return
- +59.0%
- RSI (14-day)
- 48.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.59% | +3.0% | −7.2% | +12.6% | +59.0% |
SMS Pharmaceuticals quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹197 Cr | ₹173 Cr | ₹248 Cr | ₹196 Cr | ₹242 Cr | ₹210 Cr | ₹238 Cr | ₹207 Cr |
| Revenue YoY | +18.1% | +7.4% | +1.0% | +19.2% | +23.2% | +21.4% | −4.1% | +5.6% |
| Net profit | ₹14 Cr | ₹17 Cr | ₹20 Cr | ₹19 Cr | ₹25 Cr | ₹23 Cr | ₹21 Cr | ₹20 Cr |
| Net profit YoY | +15.0% | +39.0% | +25.1% | +14.3% | +81.3% | +35.8% | +4.4% | +8.0% |
| Net margin | 7.0% | 9.9% | 8.1% | 9.5% | 10.4% | 11.0% | 8.8% | 9.8% |
| EPS | ₹1.67 | ₹2.15 | ₹2.40 | ₹2.31 | ₹2.84 | ₹2.59 | ₹3.58 | ₹2.23 |
SMS Pharmaceuticals financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹412 Cr | ₹563 Cr | ₹520 Cr | ₹522 Cr | ₹709 Cr | ₹783 Cr |
| Operating profit | ₹51 Cr | ₹91 Cr | ₹69 Cr | ₹5 Cr | ₹66 Cr | ₹92 Cr |
| Net profit | ₹33 Cr | ₹61 Cr | ₹68 Cr | ₹4 Cr | ₹49 Cr | ₹67 Cr |
| EPS (₹) | ₹4.00 | ₹7.00 | ₹7.00 | −₹1.00 | ₹6.00 | ₹8.00 |
| Cash from operations | ₹40 Cr | ₹90 Cr | ₹40 Cr | ₹22 Cr | ₹50 Cr | ₹82 Cr |
| Total debt | ₹68 Cr | ₹148 Cr | ₹150 Cr | ₹121 Cr | ₹122 Cr | ₹139 Cr |
| Shareholders' equity | ₹348 Cr | ₹411 Cr | ₹470 Cr | ₹461 Cr | ₹536 Cr | ₹640 Cr |
SMS Pharmaceuticals shareholding pattern
| Holder | 30 Jun 2025 | 11 Sep 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 66.26% | 68.07% | 68.07% | 68.07% | 68.07% | 68.07% |
| Foreign institutions | 0.03% | 0.17% | 0.28% | 0.04% | 0.31% | 0.65% |
| Domestic institutions | 3.03% | 2.88% | 2.88% | 3.21% | 3.02% | 2.83% |
| Non-institutions | 30.67% | 28.89% | 28.78% | 28.69% | 28.60% | 28.45% |
| Promoter shares pledged | 37.60% | 34.65% | 34.65% | 17.99% | 17.99% | 17.99% |
SMS Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to SMS Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ZOTAZota Health Care | ₹1,304.00 | −0.76% | −12.1% | ₹4,516 Cr | — | — |
| JSLLJeena Sikho Lifecare | ₹360.05 | −0.40% | −51.3% | ₹4,475 Cr | 20.3 | — |
| NOVARTINDNovartis India | ₹1,810.70 | +2.71% | +224.4% | ₹4,471 Cr | 48 | — |
| ORCHPHARMAOrchid Pharma | ₹876.25 | +0.06% | +20.9% | ₹4,444 Cr | 214.2 | — |
| SMSPHARMASMS Pharmaceuticals | ₹434.55 | +0.59% | +59.0% | ₹4,070 Cr | 39 | — |
| GUFICBIOGufic Biosciences | ₹401.55 | +3.43% | +9.9% | ₹4,027 Cr | 62.7 | — |
| GUJTHEMGujarat Themis Biosyn | ₹365.70 | +4.88% | −11.9% | ₹3,985 Cr | 85.4 | — |
Ask anything about SMS Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against SMSPHARMA's own history. Try: “Why has SMSPHARMA moved over the last three months?” · “Backtest a 50-day moving-average crossover on SMSPHARMA over five years” · “Compare SMSPHARMA with ZOTA on margins and valuation”
Frequently asked questions about SMS Pharmaceuticals
What is the share price of SMS Pharmaceuticals today?
SMS Pharmaceuticals (NSE: SMSPHARMA) last closed at ₹434.55 on 22 Oct 2026. Its 52-week high is ₹494.45 and its 52-week low is ₹270.10.
What is the market cap of SMS Pharmaceuticals?
SMS Pharmaceuticals' market capitalisation is ₹4,070 Cr (₹4,070 Cr) at the 22 Oct 2026 close, ranking 863rd among the NSE companies Pivot tracks.
What is the P/E ratio of SMS Pharmaceuticals?
SMS Pharmaceuticals trades at a trailing P/E of 39. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 62.7.
What is the ROE and ROCE of SMS Pharmaceuticals?
Return on equity was 10.8% in FY25 and return on capital employed was 13.4% in FY25 (consolidated figures).
Is SMS Pharmaceuticals a debt-free company?
No. SMS Pharmaceuticals' debt-to-equity ratio was 0.49 in FY25, with total debt of ₹139 Cr.
What were SMS Pharmaceuticals' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), SMS Pharmaceuticals reported revenue of ₹207 Cr, +5.6% year on year, and net profit of ₹20 Cr, +8.0% year on year.
How has SMS Pharmaceuticals stock performed over the last year?
SMS Pharmaceuticals' share price has risen 59.0% over the past year, +12.6% over three months and −7.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of SMS Pharmaceuticals?
As of 30 Jun 2026: promoters 68.07%, foreign institutions 0.65%, domestic institutions 2.83%, non-institutions 28.45%. 17.99% of promoter shares were pledged.
Who are SMS Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to SMS Pharmaceuticals by market cap are Zota Health Care, Jeena Sikho Lifecare, Novartis India, Orchid Pharma, Gufic Biosciences and Gujarat Themis Biosyn.
Is SMS Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out SMS Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SMSPHARMA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text